Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(23):1734-1735; doi:10.1093/jnci/djg129
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Goetz, M. P.
Right arrow Articles by Loprinzi, C. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goetz, M. P.
Right arrow Articles by Loprinzi, C. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2003 Oxford University Press

EDITORIALS

A Hot Flash on Tamoxifen Metabolism

Matthew P. Goetz, Charles L. Loprinzi

Affiliation of authors: Department of Oncology, Division of Medical Oncology, Mayo Clinic, Mayo Foundation, Rochester, MN.

Correspondence to: Charles L. Loprinzi, MD, Department of Oncology, Division of Medical Oncology, Mayo Clinic, Mayo Foundation, 200 First St. SW, Rochester, MN 55905 (e-mail: cloprinzi@mayo.edu)

The first 10% of the full text of this article appears below.

Tamoxifen will continue to be an important drug for the treatment of hormone-dependent breast cancer despite results suggesting that aromatase inhibitors will play an increasing role in the treatment of breast cancer for postmenopausal women (1–4). With more drugs available to treat patients with breast cancer, it is clear that patients would benefit from information that would allow their health care providers to individualize therapy. However, designing individualized therapies is complicated because for many drugs, including tamoxifen, the efficacies and toxicities differ among patients. The reasons for many of the interindividual differences are unknown.

. . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?